Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity
Findings suggest the PRMT5/GPX4 axis as a potential therapeutic target and position RK3 as a promising candidate for chemoresistant OS.
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Findings suggest the PRMT5/GPX4 axis as a potential therapeutic target and position RK3 as a promising candidate for chemoresistant OS.
Overall, this review not only elucidates the mechanisms by which mitochondrial metabolic reprogramming drives tumor immune evasion but also provides a theoretical basis for optimizing metabolism-targeted immunotherapy.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.